Galip Can Uyar: Can Second-Event Endpoints Truly Capture the Long-Term Benefit of Anti–PD-(L)1 Therapy? - Oncodaily

Galip Can Uyar: Can Second-Event Endpoints Truly Capture the Long-Term Benefit of Anti–PD-(L)1 Therapy?  Oncodaily